Roivant Sciences Ltd. — Director's Dealing 2022

Apr 26, 2022

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Roivant Sciences Ltd. (ROIV)
CIK: 0001635088
Period of Report: 2022-04-22

Reporting Person: Dexcel Pharma Technologies Ltd. (10% Owner)
Reporting Person: Dexxon Holdings Ltd. (10% Owner)
Reporting Person: Oren Dan (10% Owner)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2022-04-22	Common Shares	P	31685	$3.8289	Acquired	98840843	Direct
2022-04-25	Common Shares	P	8600	$3.9111	Acquired	98849443	Direct

Footnotes

F1: Dexcel Pharma Technologies Ltd. ("Dexcel") is the direct beneficial holder of 684,130 common shares. Dexxon Holding Ltd. ("Dexxon") is the direct beneficial holder of 98,165,313 common shares. Dan Oren is the Executive Chairman of Dexcel and the sole director of Dexxon and is ultimately the sole shareholder of each entity.

F2: The price reported in Column 4 is the weighted average price. The common shares were purchased in multiple transactions at prices ranging from $3.685 to $3.88.

F3: The price reported in Column 4 is the weighted average price. The common shares were purchased in multiple transactions at prices ranging from $3.825 to $3.99.

F4: The Reporting Persons hereby undertake to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected.